CD8A and neoplasm: The combination of FMT and PD-1 blockade stimulates mucosal-associated invariant T and CD56+CD8+ T cells in peripheral blood mononuclear cells and upregulates the expression of human leukocyte antigen class II genes CD74 and granzyme K on CD8+ T cells at the tumor site to improve the therapeutic effect of ICIs (65).